NEO · CIK 0001077183

What NeoGenomics, Inc. told the SEC could break it.

2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.

A limited set so far, we surface every cited disclosure we’ve extracted for NEO. More may follow as additional filings are processed.

In its own words

What could break it.

Regulatory & policy

Reimbursement + fraud/abuse + lab regulation — payer coverage/reimbursement (Medicare ~13% of revenue, PAMA/MolDx), False Claims Act/Stark exclusion risk, CLIA and FDA LDT oversightmedium
NeoGenomics's revenue depends on adequate payer coverage and reimbursement: Medicare and other government payers were ~13% of revenue, and CMS imposes extensive requirements on diagnostic providers (PAMA-driven rate cuts, MolDx coverage decisions). It is subject to strict fraud-and-abuse laws (False Claims Act, anti-kickback, Stark) where non-compliance can bring substantial penalties and exclusion from Medicare/Medicaid, plus CLIA lab certification and evolving FDA oversight of laboratory-developed tests (LDTs). Inadequate coverage, reimbursement-rate cuts, an adverse audit, or new LDT regulation would directly compress net revenue. A high, structural diagnostic-lab reimbursement-and-compliance exposure.
“Our net revenue will be diminished if payers do not adequately cover or reimburse our services. Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid, and other governmental payer programs.”
SEC filing →As of 2026

Supplier concentration

Dependence on third parties for laboratory and research equipment, reagents and supplies; tariff/supply-chain cost pressure on imported lab inputsmedium
NeoGenomics depends on third parties for the laboratory and research equipment, reagents and supplies that its cancer-diagnostics testing requires. If these supplies or services become unavailable or are disrupted, it would have to seek alternate suppliers and may be unable to perform its tests on a timely basis — a real risk given specialized sequencers, instruments and proprietary reagents (often single/limited-source) that are hard to re-qualify. It also flags supply-chain disruptions and tariffs as cost/availability pressures it must mitigate through supply-chain adjustments and pricing. The suppliers are not named, so this is an equipment/reagent supply-dependence risk rather than a named edge. A material lab-input supply dependence.
“We depend on third parties for our laboratory and research equipment and supplies. If these supplies or services become unavailable or are disrupted, we would have to seek alternate suppliers”
SEC filing →As of 2026

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch

What could break it.

Regulatory & policy

Reimbursement + fraud/abuse + lab regulation — payer coverage/reimbursement (Medicare ~13% of revenue, PAMA/MolDx), False Claims Act/Stark exclusion risk, CLIA and FDA LDT oversightmedium
NeoGenomics's revenue depends on adequate payer coverage and reimbursement: Medicare and other government payers were ~13% of revenue, and CMS imposes extensive requirements on diagnostic providers (PAMA-driven rate cuts, MolDx coverage decisions). It is subject to strict fraud-and-abuse laws (False Claims Act, anti-kickback, Stark) where non-compliance can bring substantial penalties and exclusion from Medicare/Medicaid, plus CLIA lab certification and evolving FDA oversight of laboratory-developed tests (LDTs). Inadequate coverage, reimbursement-rate cuts, an adverse audit, or new LDT regulation would directly compress net revenue. A high, structural diagnostic-lab reimbursement-and-compliance exposure.
“Our net revenue will be diminished if payers do not adequately cover or reimburse our services. Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid, and other governmental payer programs.”
SEC filing →As of 2026

Supplier concentration

Dependence on third parties for laboratory and research equipment, reagents and supplies; tariff/supply-chain cost pressure on imported lab inputsmedium
NeoGenomics depends on third parties for the laboratory and research equipment, reagents and supplies that its cancer-diagnostics testing requires. If these supplies or services become unavailable or are disrupted, it would have to seek alternate suppliers and may be unable to perform its tests on a timely basis — a real risk given specialized sequencers, instruments and proprietary reagents (often single/limited-source) that are hard to re-qualify. It also flags supply-chain disruptions and tariffs as cost/availability pressures it must mitigate through supply-chain adjustments and pricing. The suppliers are not named, so this is an equipment/reagent supply-dependence risk rather than a named edge. A material lab-input supply dependence.
“We depend on third parties for our laboratory and research equipment and supplies. If these supplies or services become unavailable or are disrupted, we would have to seek alternate suppliers”
SEC filing →As of 2026